Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NAMPT | P43490 | 10/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835804 | 0.83 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2NAMPTL3MBTL1MAPT | |
| SCHEMBL3835485 | 0.83 | QDPR (0.53) | ALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL3822163 | 0.81 | AKT1 (0.43) | ALDH1A1SMN1; SMN2NAMPTL3MBTL1 | |
| SCHEMBL3836373 | 0.80 | NAMPT (0.51) | ALDH1A1SMN1; SMN2NAMPTDPP4MAPT | |
| SCHEMBL3834877 | 0.79 | HRH4 (0.45) | — | |
| SCHEMBL3830930 | 0.79 | NAMPT (0.59) | ALDH1A1NAMPTL3MBTL1 | |
| SCHEMBL3834475 | 0.79 | NAMPT (0.54) | ALDH1A1SMN1; SMN2NAMPTCCNT1CDK9 | |
| SCHEMBL3831967 | 0.78 | NAMPT (0.46) | ALDH1A1NAMPTDPP4 | |
| SCHEMBL3837172 | 0.77 | DPP4 (0.46) | SMN1; SMN2NAMPTDPP4DPP9 | |
| SCHEMBL4148780 | 0.74 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091916-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | AstraZeneca AB (SE) | 2009-08-26 | — | — | EP | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | ALDH1A1 1156/4885SMN1; SMN2 2699/4885NAMPT 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.